In vitro activity of voriconazole against selected fungi

Medical Mycology

Volumn 36, Issue 4, 1998, Pages 239-242

  McGinnis, M R ^a   Pasarell, L ^a   Sutton, D A ^b   Fothergill, A W ^b   Cooper Jr , C R ^a   Rinaldi, M G ^b,c  

^a University of Texas Medical Branch School of Medicine   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

^c SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

Author keywords

Amphotericin B; Fluconazole; Itraconazole; Voriconazole

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; ITRACONAZOLE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; ASCOMYCETES; BASIDIOMYCETES; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; STANDARD; TECHNIQUE; ZYGOMYCETES;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; ASCOMYCOTA; BASIDIOMYCOTA; FLUCONAZOLE; FUNGI; HUMANS; ITRACONAZOLE; MICROBIAL SENSITIVITY TESTS; PYRIMIDINES; TRIAZOLES; ZYGOMYCOTA;

ACREMONIUM STRICTUM; ASCOMYCOTA; BASIDIOMYCOTA; EXOPHIALA DERMATITIDIS; FUNGI; FUSARIUM; FUSARIUM OXYSPORUM; FUSARIUM SOLANI; ZYGOMYCETES;

EID: 0031949030     PISSN: 13693786     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-280X.1998.00153.x     Document Type: Article

References (19)

1. Richardson K, Bell AS, Dickinson RP, Narayanaswami S, Ray SJ. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: synthesis and SAR. In: Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1995: abstract F69, 125.
2. Troke PF, Bell AS, Dickinson RP, et al. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: discovery and antifungal properties. In: Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1995: abstract F70, 125.
3. Jezequel SG, Clark M, Cole S, Evans KE, Wastall P. UK-109, 496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: pre-clinical pharmacokinetics. In: Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1995: abstract F76, 126.
4. Jezequel SG, Clark M, Evans K, Roffey S, Wastall P, Webster R. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: disposition in animals. In: Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1995: abstract F77, 126.
5. Patterson BE, Coates PE. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: pharmacokinetics in man. In: Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1995: abstract F78, 126.
6. Patterson BE, Roffey S, Jezequel SG, Jones B. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: disposition in man. In: Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1995: abstract F79, 126.
7. Sanati H, Belanger P, Fratti R, Ghannoum M. A new triazole, voriconazole (UK-109, 496), blocks sterol biosynthesis in Candida albicans and Candida krusei. Antimicrob Agents Chemother 1997; 41: 2492-6.
8. Belanger P, Nast CC, Fratti R, Sanati H, Ghannoum M. Voriconazole (UK-109, 496) inhibits the growth and alters the morphology of fluconazole-susceptible and -resistant Candida albicans. Antimicrob Agents Chemother 1997; 41: 1840-2.
9. Barchiesi F, Restrepo M, McGough DA, Rinaldi MG. In vitro activity of a new antifungal triazole: UK-109,496. In: Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1995: abstract F71, 125.
10. Barry AL, Brown SD. In vitro studies of two triazole antifungal agents (voriconazole [UK-109,496] and fluconazole) against Candida species. Antimicrob Agents Chemother 1996; 40: 1948-9.
11. Espinel-Ingroff A. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J Clin Microbiol 1998; 36: 198-202.
12. McGinnis MR, Pasarell L, Sutton DA, Fothergill AW, Cooper CR Jr, Rinaldi MG. In vitro evaluation of voriconazole against some clinically important fungi. Antimicrob Agents Chemother 1997; 41: 1832-4.
13. Radford SA, Johnson EM, Warnock DW. In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens. Antimicrob Agents Chemother 1997; 41: 841-3.
14. Murphy M, Bernard EM, Ishimaru T, Armstrong D. Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 1997; 41: 696-8.
15. Martin MV, Yates J, Hitchcock CA. Comparison of voriconazole (UK-109,496) and itraconazole in prevention and treatment of Aspergillus fumigatus endocarditis in guinea pigs. Antimicrob Agents Chemother 1997; 41: 13-16.
16. George D, Miniter P, Andriole VT. Efficacy of UK-109496, a new azole antifungal agent, in an experimental model of invasive aspergillosis. Antimicrob Agents Chemother 1996; 40: 86-91.
17. National Committee for Clinical Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; approved standard M27-A. Villanova, PA: National Committee for Clinical Laboratory Standards, 1997.
18. McGinnis MR, Rinaldi MG. Antifungal drugs: mechanisms of action, drug resistance, susceptibility testing, and assays of activity in biologic fluids. In: Lorian V, ed. Antibiotics in Laboratory Medicine, 4th edn. Baltimore: Williams and Wilkins, 1996: 176-211.
19. Rex JH, Pfaller MA, Galgiani JN, et al. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin Infect Dis 1997; 24: 235-7.